

Curriculum vitae

Prof Giovanni Squadrito curriculum vitae.

Prof. Giovanni Squadrito nato a Messina il 26/12/1967

Istruzione e Formazione.

-Maturità classica presso il Liceo-Ginnasio Francesco Maurolico di Messina (anno scolastico 1985-86, votazione di 60/60).

-Laurea in Medicina e Chirurgia presso l'Università degli Studi di Messina (15/07/1992, votazione media 30 negli esami di profitto, votazione di 110/110 e lode accademica); tesi dal titolo: "Infezione occulta da HBV wild type e da variante e-minus in pazienti con epatopatia cronica HCV correlata" che ottenne dignità di stampa (relatore prof. Domenico Ceruso).

-Specializzazione in "Medicina Interna" presso l'Università degli Studi di Messina il 29/10/1998, votazione di 50/50 e lode, tesi dal titolo "Variabilità genomica della regione NS5A del virus dell'epatite C e risposta alla terapia con Interferone alfa".

Esperienze professionali presso centri di ricerca esteri.

- Dal 1/02/1993 al 25/03/1994 Research Fellow presso "Departments of Medicine and of Histopathology, Royal Free Hospital, University of London" diretti rispettivamente dai Prof.ri G.M. Dusheiko e P. Scheuer. Qui si è occupato di ricerca nel campo delle epatiti virali ed in particolare di quelle da virus C, all'epoca di recente individuazione nella fattispecie ha messo a punto la tecnica di ibridazione in situ su tessuto epatico ottenuto da biopsie di pazienti affetti da suddetto virus. Durante il suddetto periodo ha anche frequentato sia il reparto che gli ambulatori del Liver Center, avendo la possibilità di assistere i pazienti affetti da varie patologie epatiche che si recavano per consulenza dalla Prof.ssa Dame Sheila Scherlock.

- Dall'ottobre 1994 al giugno del 1996 Research Fellow presso l'"INSERM U370 Unitè de Carcinogènese hépatique et virologie moléculaire, Université Paris V, Laboratoire de Biologie Cellulaire" (Direttore Prof. Christian Brèchet), occupandosi prevalentemente di studi nel campo della biologia molecolare del virus dell'epatite C.

Attività di ricerca

L'attività di ricerca si è svolta in gran parte presso la struttura internistica ad indirizzo epatologico (U.O.C. Epatologia Clinica e Biomolecolare) diretta dal Prof Giovanni Raimondo presso l'Azienda

Ospedaliera Universitaria “Gaetano Martino” di Messina, ed ha seguito diversi filoni di ricerca: ruolo della variabilità genomica dei virus B e C dell’epatite sia sulla risposta antivirale che sulla carcinogenesi epatica, infezione occulta da virus B dell’epatite, complicanze della cirrosi epatica. Ha inoltre - soprattutto nella parte iniziale della sua attività - collaborato con il gruppo di ricerca di Farmacologia diretto dal Prof. AP Caputi presso l’Università degli Studi di Messina, occupandosi di tematiche rivolte allo studio dei meccanismi molecolari del danno da ischemia e ri-perfusione, alle alterazioni endoteliali in donne in epoca post-menopausale.

Attività assistenziale

Dalla data di immissione in ruolo come Ricercatore Universitario (1.10.1998) a tutt’oggi ha svolto ininterrottamente attività assistenziale presso la struttura dipartimentale di Medicina Interna che negli anni ha avuto diverse denominazioni fino a quella attuale di Dipartimento Assistenziale Integrato di Medicina Interna presso il Policlinico Universitario di Messina (Denominazione attuale Azienda Ospedaliera Universitaria “Gaetano Martino”). In particolare egli ha svolto sia attività presso la struttura internistica ad indirizzo epatologico (U.O.C. Epatologia Clinica e Biomolecolare) diretta dal Prof Giovanni Raimondo che attività interdipartimentale compresi turni di guardia con impegni nelle varie Unità Operative (Medicina Interna, Geriatria, Nefrologia) nel contesto del Dipartimento Assistenziale Integrato di Medicina Interna.

Attività assistenziale attuale.

Responsabile del Programma Interdipartimentale di “Diagnostica delle malattie Epatiche” presso l’Azienda Ospedaliera Universitaria “G Martino” di Messina.

Vicario del Direttore dell’UOC di Epatologia Clinica e Biomolecolare (Prof. Giovanni Raimondo).

Vicario del Direttore del Dipartimento Assistenziale Integrato di Medicina Interna (Prof Antonino Saitta).

Attività accademica.

- Ricercatore Universitario di Medicina Interna (SSD MED 09) presso l’Università degli Studi di Messina dal mese di Ottobre 1998 al Febbraio 2011.

- Professore Associato di Medicina Interna (SSD MED 09) presso l’Università degli studi di Messina dal 01.03.2011 al 28.10.2015.

- Professore Ordinario di Gastroenterologia (SSD MED 12) presso l’Università degli studi di Messina dal 28.10.2015 a tutt’oggi.

Dall’entrata in ruolo di Universitario di Medicina Interna ha svolto la sua attività presso il Dipartimento di Medicina Interna e Terapia Medica poi denominato Dipartimento di Medicina

Clinica e Sperimentale, con un intermezzo dal marzo 2015 al dicembre 2018 presso il Dipartimento di Patologia Umana.

-Coordinatore del Dottorato di Ricerca in Biotecnologie Mediche e Chirurgiche dell'Università degli Studi di Messina.

Attività Didattica

Docente di Gastroenterologia, di Semeiotica Medica nel Corso integrato di Semeiotica e Metodologia Clinica, Fisiopatologia Clinica e Medicina Interna, presso il corso di Laurea Magistrale in Medicina e Chirurgia dell'Università degli Studi di Messina e di Gastroenterologia presso i corsi di Laurea di Infermieristica e di Tecniche Radiologiche.

Docente presso le Scuole di Specializzazione:

- Medicina Interna della Facoltà di Medicina e Chirurgia dell'Università degli studi di Messina;
- Gastroenterologia della Facoltà di Medicina e Chirurgia dell'Università' degli Studi Di Palermo.

Attività Editoriale e Societaria

Revisore per numerose riviste scientifiche internazionali.

Socio delle seguenti associazioni scientifiche:

- Associazione Italiana per lo Studio del Fegato (A.I.S.F.);
- Società di Medicina Interna (SIMI);
- Società Italiana di Gastroenterologia (SIGE).

Durante il triennio 2010-12 il Prof Squadrito è stato componente del comitato nazionale dell'Associazione Italiana per lo Studio del Fegato (A.I.S.F.) e nel triennio 2012-2014 è stato membro nel consiglio direttivo della Fondazione per la Ricerca in campo Epatologico (FIRE).

Il prof Giovanni Squadrito è stato invitato quale relatore presso numerosi congressi nazionali e internazionali.

I prodotti della ricerca svolta dal prof Giovanni Squadrito sono esitati nella pubblicazione di 122 lavori su riviste internazionali con H index di 42 (Scopus), citazioni totali 6710, Impact Factor totale 873.924 Impact factor medio 7.59.

Prof Giovanni Squadrito

Elenco totale delle pubblicazioni pubblicate per estenso su riviste internazionali

1) Hepatitis C virus-polymerase chain reaction of routinely processed liver biopsies.

Batanony M.H., Savage K., Jacobs R., **Squadrito G.**, Brown D., Saleh S.M., Raouf A.A., Amer K.M., Dusheiko G.M., Scheuer P.J., Dhillon A.P.

J. Med. Virol., 43: 04-380-85, 1994

Impact factor 1.988

2) Inapparent "wild-type" and "e-minus variant" HBV infection in patients with HCV-related chronic hepatitis.

Sardo MA, Rodinò G, Brancatelli S, Pernice M, Campo S, **Squadrito G**, Russo F, Raimondo G.

Liver 1994 Oct; 14(5):241-4.

Impact factor 4.116

3) Hepatitis B E antigen detection in formalin-fixed liver biopsy specimens. A tool to investigate wild-type and E-minus variant HBV infection.

Villari D, Pollicino T, Spinella S, Russo F, Campo S, Rodinò G, **Squadrito G**, Longo G, Raimondo G.

Am J Clin Pathol. 1995; 103(2): 136-40.

Impact Factor 2.413

4) G-619, A Dual Thromboxane synthase inhibitor and thromboxane A(2) receptor antagonist, inhibits tumor necrosis factor ALPHA biosynthesis.

Altavilla D, Squadrito F, Canale P, Iocolano M, **Squadrito G**, Campo GM, Serranò M, Sardella A, Urna G, Spigoli GI, Caputi A.P.

Eur Journal Pharmacol 1995; 286; 251-56.

Impact Factor 3.04

5) Tumor –Necrosis –Factor induces E-Selectin production in splanchnic artery-occlusion shock.

Altavilla D, Squadrito F, Canale P, Iocolano M, Campo GM, **Squadrito G**, Saitta A, Caputi A.P.

Am J Phys Heart Circ Physiol. 1995; 37; 1412-17.

Impact Factor 3.569

6) Heterogeneity of HBV genome.

Raimondo G, Pollicino T, Campo S, **Squadrito G**.

Ital J Gastroenterol. 1995; 27(2): 88-90.

Impact Factor 3.287

7) Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.

Squadrito F, Altavilla D, **Squadrito G**, Campo GM, Iocolano M, Canale P, Rossi F, Saitta A, Caputi A.P.

British J. Pharmacol. 1996; 119:23-28

Impact Factor 3.838

8) Chronic hepatitis in patients with active hepatitis B virus and hepatitis C virus combined infections: a histological study.

Villari D, Pernice M, Spinella S, **Squadrito G**, Rodinò G, Brancatelli S, Longo G, Raimondo G.

Am J Gastroenterol. 1995; 90(6): 955-8

Impact Factor 10.237

9) Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin's lymphoma and without liver disease.

Musolino C, Campo S, Pollicino T, **Squadrito G**, Spatari G, Raimondo G.

Haematologica. 1996; 81(2): 162-4

Impact Factor 9.09

10) Leukocyte integrin very late antigen-4/vascular cell adhesion molecule-1 adhesion pathway in splanchnic artery occlusion shock.

Squadrito F, Altavilla D, Ammendolia L, **Squadrito G**, Campo GM, Canale P, Iocolano M, Musolino C, Alonci A, Saitta A, Rossi F, CAPUTI A.P.

Eur J Pharmacol 1996; 318; 153-60.

Impact Factor 3.04

11) Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction.

Squadrito F, Saitta A, Altavilla D, Iocolano M, Canale P, Campo GM, **Squadrito G**, Ditano G, Mazzu A, Caputi A.P.

Infl Research 1996; 45; 14-9.

Impact Factor 2.99

12) Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21-aminosteroid U-74389G, a new inhibitor of lipid peroxidation.

Campo GM, Squadrito F, Altavilla D; **Squadrito G**, Avenoso, Canale P, Iocolano M, Sperandeo A, Caputi A.P.

J Pharmacol Exper Therap 1996; 277; 333-40.

Impact Factor 3.867

13) Endotoxin tolerance impairs a pertussis-toxin-sensitive G- protein regulating tumour necrosis factor release by macrophages from tumour-bearing rats

Altavilla D, Squadrito F, Canale P, Iocolano M, Campo GM, **Squadrito G**, Urna G, Sardella A, Caputi AP.

Pharmacol Res 1996; 33; 203-09.

Impact Factor 4.897

14) The effects of recombinant human granulocyte-colony stimulating factor on vascular dysfunction and splanchnic

ischaemia- reperfusion injury.

Squadrito F, Altavilla D, **Squadrito G**, Campo GM, Iocolano M, Ammendolia L, Arlotta M, Saitta A; Caputi A.P.
British J Pharmacol 1997; 120; 333-39. Impact Factor 3.838

15) The involvement of tumour necrosis factor-alpha in the protective effects of 17 beta oestradiol splanchnic ischaemia-reperfusion injury.

Squadrito F, Altavilla D, **Squadrito G**, Campo GM, Arlotta M, Arcoraci V, Minutoli L, Saitta A, Caputi AP.
British J Pharmacol 1997; 121; 1782-88. Impact Factor 3.838

16) Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat.

Squadrito F, Altavilla D, **Squadrito G**, Campo GM, Arlotta M, Arcoraci V, Minutoli L, Serrano M, Saitta A, Caputi AP
Eur J Pharmacol 1997; 335; 185-92 Impact Factor 3.04

17) Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C.

Le Gun B, **Squadrito G**, Nalpas B, Berthelot P, Pol , Brechot C.

Hepatology. 1997; 25: 1250-4. Impact Factor 14.079

18) Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, Pol , Brechot C

Gastroenterology. 1997; 113: 567-72. Impact Factor 20.773

19) Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats.

Squadrito F, Altavilla D, **Squadrito G**, Saitta A, Campo GM, Arlotta M, Quartarone C, Ferlito M, Caputi AP.

Eur J Pharmacol 1998; 364; 159-68. Impact Factor 3.04

20) Sulfatide reduces leucocyte accumulation and reverts vascular failure in splanchnic artery occlusion shock.

Squadrito F, Altavilla D, **Squadrito G**, Saitta A, Campo GM, Arlotta M, Quartarone C, Minutoli L, Ferlito M, Saitta A, Caputi AP.

Eur J Pharmacol 1998; 361; 101-08. Impact Factor 3.04

21) Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection.

Leone F, Zylberberg H, **Squadrito G**, Le Gun B, Berthelot P, Pol , Brechot C

J Hepatol. 1998; 29: 689-94.

Impact Factor 15.04

22) Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock

Squadrito F; Guarini S; Altavilla D.; **Squadrito G**, Campo GM, Arlotta M, Quartarone C, Saitta A, Cucinotta D, Bazzani C, Cainazzo MM; Mioni C; Bertolini A; Caputi AP.

British J Pharmacol 1999; 128; 816-22

Impact Factor 3.838

23) Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury

Deodato B; Altavilla D, **Squadrito G**, Campo GM, Arlotta M, Minutoli L, Saitta A, Cucinotta D, Calapai G, Caputi AP, Miano M, Squadrito F.

British J Pharmacol 1999; 128; 1683-90

Impact Factor 3.838

24) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock

Squadrito F, Altavilla D, **Squadrito G**, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP.

British J Pharmacol 1999; 127; 482-88

Impact Factor 3.838

25) Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock

Squadrito F, Altavilla D, **Squadrito G**, Ferlito M, Campo GM, Arlotta M, Grimaldi S, Quartarone C, Saitta A, Caputi AP

British J Pharmacol 1999; 127; 498-504

Impact Factor 3.838

26) The lazaroïd, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock

Altavilla D, Squadrito F, Campo GM, **Squadrito G**, Arlotta M, Urna G, Sardella A, Quartarone C, Saitta A, Caputi AP.

Eur J Pharmacol 1999; 369; 49-55.

Impact Factor 3.04

27) Epidemiological and virological analysis of couples infected with hepatitis C virus.

Zylberberg H, Thiers V, Lagorce D, **Squadrito G**, Leone F, Berthelot P, Brechot C, Pol S.

Gut 1999; 45: 112-6.

Impact Factor 17.016

28) Long term response to interferon alpha is unrelated with "interferon sensitivity determining region" variability in patients with chronic hepatitis c virus-1b infection.

Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, Lo Iacono O, Siciliano R, Levrero M, Raimondo G.

J Hepatol 1999; 30: 1023-7

Impact Factor 15.04

29) Effect of sulfatide on acute lung injury during endotoxemia in rats

Squadrito F, Bagnato G, Altavilla D, Ferlito M, Campo GM, **Squadrito G**, Urna G, Sardella A, Arlotta M, Minutoli L, Quartarone C, Saitta A, Caputi AP.

Life Sciences. 1999; 65; 2541-52

Impact Factor 3.234

30) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.

Cacciola I, Pollicino T, **Squadrito G**, Cerenzia G, Orlando ME, Raimondo G

N Engl J Med 1999; 1; 341: 22-6

Impact Factor 79.258

31) Inhibition of lipid peroxidation reduces the inflammatory response and increases early-immediate genes expression in carbon tetrachloride-induced rat liver injuri.

Squadrito F, Altavilla D, **Squadrito G**, Calò M, Naccari F, Grimaldi S, Miano M, Caputi AP.

Pharmacol Res 1999; 103

Impact Factor 4.897

32) Protective effects of Cyclosporin-A in splanchnic artery occlusion shock

Squadrito F, Altavilla D, **Squadrito G**, Ferlito M, Deodato B, Arlotta M, Minutoli L, Campo GM, Bova A, Quartarone C, Urna G, Sardella A, Saitta A; Caputi AP

British J Pharmacol 1999; 130; 339-344

Impact Factor 3.838

33) Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats.

Squadrito F, Altavilla D, **Squadrito G**, Saitta A, Cucinotta D, Minutoli L, Deodato B, Ferlito M, Campo GM, Bova A, Caputi AP.

Cardiov Res 2000; 45; 454-62.

Impact Factor 6.29

34) IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappa B and reduces the inflammatory response in myocardial ischaemia-reperfusion injury

Altavilla D, Deodato B, Campo GM, Arlotta M, Miano M, **Squadrito G**, Saitta A, Cucinotta D, Ceccarelli S, Ferlito M, Tringali M; Minutoli L, Caputi AP, Squadrito F

Cardiov Res 2000; 47; 515-18.

Impact Factor 6.29

35) Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.

Cacciola I, Pollicino T, **Squadrito G**, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G.

Hepatology. 2000; 31: 507-12.

Impact Factor 14.079

36) Occult hepatitis B virus infection.

Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, Pollicino T, **Squadrito G**, Tiribelli C.

Dig Liver Dis. 2000;32:822-6.

Impact Factor 3.287

37) Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia-reperfusion injury

Squadrito F, Altavilla D, **Squadrito G**, Saitta A, Deodato B, Arlotta M, Minutoli L, Quartarone C, Ferlito M, Caputi + AP.

J Mol Cell Cardiol 2000; 32; 429-40.

Impact Factor 5.296

38) The reduction of myocardial damage and leukocyte polymorphonuclear accumulation following coronary artery occlusion by the tyrosine kinase inhibitor tyrphostin AG 556

Altavilla D, Squadrito F, Campo GM, Saitta A, **Squadrito G**, Quartarone C, Deodato B, Arlotta M, Ferlito M, Minutoli L, Tringali M, Urna G, Sardella A, Caputi AP.

Life Sciences. 2000; 67; 2615-29

Impact Factor 3.234

39) Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women

Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, D'anna R, Lasco A, **Squadrito G**, Gaudio A, Cancellieri F, Arcoraci V, Squadrito F.

Art Thromb Vascul Biol 2000; 21; 1512-19.

Impact Factor 6.089

40) Nuclear factor-kappa B as a target of cyclosporin in acute hypovolemic hemorrhagic shock

Altavilla D, Saitta A, Guarini S, Galeano M, **Squadrito G**, Santamaria LB, Venuti FS, Bazzani C, Bertolini A, ; Squadrito F.

Cardiovas Res 2001; 52; 143-152

Impact Factor 6.29

41) Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse.

Altavilla D, Saitta A, Cucinotta D, Galeano M, Deodato B, Colonna M, Torre V, Russo G, Sardella A, Urna G, Campo GM, Cavallari V, **Squadrito G**, Squadrito F.

Diabetes 2001; 50-3; 667-74.

Impact Factor 7.273

42) Oxidative stress causes nuclear Factor-kappa B activation in acute hypovolemic hemorrhagic shock

Altavilla D, Saitta A, Guarini S, Galeano M, **Squadrito G**, Cucinotta D, Santamaria LB, Mazzeo AT, Campo GM, Ferlito M, Minutoli L, Bazzani C, Bertolini A, Caputi AP, Squadrito F.

Free Rad Biol Med 2001; 30; 1055-61

Impact Factor 6.02

43) Reduction of carbon tetrachloride-induced rat liver injury by IRFI 042, a novel dual vitamin E-like antioxidant

Campo GM, Squadrito F, Ceccarelli S, Calò M, Avenoso A, Campo S, **Squadrito G**, Altavilla D.

Free Rad Res 2001; 34-4; 379-83.

Impact Factor 3.038.

- 44) The phytoestrogen alpha-zearalenol reverses endothelial dysfunction induced by oophorectomy in rats
Altavilla D, Saittava A, Galeano M, **Squadrito G**, Marino D, Minutoli L, Calapai G, Deodato B, D'anna R, Corrado F, Caputi AP, Squadrito F.
Lab Inv 2001; 81; 125-31. Impact Factor 4.254
- 45) Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin
Campo S, Restuccia T, Villari D, Raffa G, Cucinotta D, **Squadrito G**, Pollicino T, Raimondo G.
Liver. 2001 ;21-4:233-6. Impact factor 4.5
- 46) Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection.
Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, Brancatelli S, Di Marco V, Picciotto A, Colucci G, Craxì A, Raimondo G
Am J Gastroenterol 2002; 97 (6):1518-1523 Impact Factor 10.237
- 47) The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women
Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, Caputi AP, **Squadrito G**.
Atherosclerosis 2002; 163/2; 339-47. Impact Factor 4.467
- 48) Inhibition of nuclear factor-kappa B activation by IRFI 042, protects against endotoxin-induced shock
Altavilla D, **Squadrito G**, Minutoli L, Deodato B, Bova A, Sardella A, Seminara P, Passaniti M, Urna G, Venuti SF, Caputi AP, Squadrito F.
Card Res 2002; 54/3; 684-93. Impact Factor 6.29
- 49) Immunohistochemical evidence of lactoferrin in hepatic biopsies of patients with viral or cryptogenetic chronic liver disease.
Tuccari G, Vilari D, Giuffrè G, Simone A, **Squadrito G**, Raimondo G, Barresi G.
Histol Histopathol. 2002; 17: 1077-1083. Impact factor 2.025
- 50) Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.
Cacciola I, Cerenzia G, Pollicino T, **Squadrito G**, Castellaneta S, Zanetti AR, Mieli-Vergani G, Raimondo G.
J Hepatol 2002; 36(3):426-432 Impact Factor 15.04
- 51) Is investigation of hepatitis C virus (HCV)-NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G.

J Viral Hepatitis 2002; 5: 360-369.

Impact Factor 4.237

52) Evidence for a role of nuclear factor-kappa B in acute hypovolemic hemorrhagic shock

Altavilla D, Saitta A, **Squadrito G**, Galeano M, Venuto SF, Guarini S, Bazzani C, Bertolini A, Caputi AP, Squadrito F.

Surgery 2002; 131-1; 50-58

Impact Factor .3.574

53) Efferent vagal fibre stimulation blunts nuclear factor-kappa B activation and protects against hypovolemic hemorrhagic shock

Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H, **Squadrito G**, Minutoli L, Bertolini A, Marini R, Adamo EB, Venuti FS, Squadrito F.

Circulation 2003; 107-8; 1189-94.

Impact Factor .18.8

54) Effect of recombinant adeno-associated virus vector-mediated vascular endothelial growth factor gene transfer on wound healing after burn injury.

Galeano M, Deodato B, Altavilla D, **Squadrito G**, Seminara P, Marini HR, STAGNO D'ALCONTRES F, Colonna MR, Calo' M, Lo Cascio P, Torre V; Giacca M; Venuti FS, Squadrito F.

Crit Care Med 2003; 31-4; 1017-25.

Impact Factor .6.63

55) High prevalence of non-organ-specific autoantibodies in hepatitis C virus infected cirrhotic patients from southern Italy.

G Squadrito, M Previti, M Lenzi, E Pagano Le Rose, G Caccamo, T Restuccia, E Di Cesare, T Pollicino, G Raimondo.

Digestive Diseases and Science, 2003, 48: 349-53.

Impact Factor 2.819

56) TT virus has ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples.

T Pollicino, G Raffa, **G Squadrito**, I Cacciola, S Brancatelli, C Alafaci, M Gioffrè Florio, G Raimondo.

J Viral Hepatitis 2003, 10: 95-102

Impact Factor 4.237

57) Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.

Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxì A, Cacciola I, **Squadrito G**, Raimondo G.

J Biol Regul Homeost Agents. 2003; 17:172-5.

Impact Factor 1.397

58) Clinical Virology of hepatitis B virus infection.

G.Raimondo, T. Pollicino, **G. Squadrito**

59) Gene transfer of I kappa B alpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury
Squadrito F, Deodato B, **Squadrito G**, Seminara P, Passaniti M, Venuti FS, Giacca M, Minutoli L, Adamo EB, Bellomo M, Marini R, Galeano M, Marini H, Altavilla D.

Lab Invest 2003; 83-8; 1097-1104.

Impact Factor 4.254

60) Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study
Squadrito F; Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, D'anna R, Corrado F, Ruggeri P, Frisina N, **Squadrito G**.

Am J Med 2003; 114; 470-76.

Impact Factor 5.561.

61) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection

Pollicino T, **Squadrito G**, Cerenzia G, Cacciola I, Raffa G, Craxì A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G.

Gastroenterology. 2004;126:102-10.

Impact Factor 20.773

62) Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases.

Raimondo G, Costantino L, Cacciamo G, Pollicino T, **Squadrito G**, Cacciola I, Brancatelli S.

J Hepatol. 2004; 40: 515-9

Impact Factor 15.04

63) Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and Placebo-controlled Study

Crisafulli A, Marini H, Bitto A, Altavilla D, **Squadrito G**, Romeo A, Adamo EB, Marini R, D'anna R, Corrado F, Bartolone S, Frisina N, Squadrito F.

Menopause 2004; 11-4; 400-04.

Impact Factor 2.673

64) Peginterferon alfa 2-b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial.

Bruno S, Cammà C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebutti C, Di Bona D, Colombo M, Craxì A, Mondelli MU, Pinzello G.

J Hepatol. 2004; 41: 474-481

Impact Factor 15.504

65) Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.

Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Alamasio PL, Pizzetto M, Craxì A for the Italian Association for the Study of the Liver (AISF) Lamivudine study group, Italy

Hepatology 2004; 40: 883-891.

Impact Factor 14.079

66) Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin system in early postmenopausal women

Crisafulli A, Altavilla D, **Squadrito G**, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'anna R, Corrado F, Bartolone S, Frisina N, Squadrito F.

J Clin Endoc 2004; 89-1; 188-92.

Impact Factor 5.789

67) Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in one-year follow up study.

Cacciola I, Spatari G, Pollicino T, Costantino L, Zimbaro G, Brancatelli S, Fenga C, Caccamo G, **Squadrito G**, Raimondo G.

Liver Int. 2005 ;25:555-63.

Impact factor 4.5

68) Effects of the phytoestrogen Genistein on cardiovascular risk in postmenopausal women.

Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D., Frisina N, Corrado F, D'anna R, **Squadrito G**, Adamo EB, Marini R, Romeo A, Cancellieri F, Buemi M, Squadrito F.

Menopause 2005; 12; 186-92.

Impact factor 2.673

69) Protective effects of antioxidant raxofelast in alcohol-induced liver disease in mice.

Altavilla D, Marini H, Seminara P, **Squadrito G**, Minutoli L, Passaniti M, Bitto A, Calapai G, Calò M, Caputi AP, Squadrito F.

Pharmacology 2005; 74; 6-14.

Impact factor 1.538

70) Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds.

Altavilla D, Galeano M, Bitto A, Minutoli L, **Squadrito G**, Seminara P, Venuti FS, Torre V, Calò M, Colonna MR, Lo Cascio P, Giugliano G, Scuderi N, Mioni C, Leone S, Squadrito F.

Shock 2005; 24-1; 85-91.

Impact factor 3.005

71) What is the clinical impact of occult hepatitis B virus infection?

Raimondo G, Pollicino T, **Squadrito G**.

The Lancet 2005; 365:638-40

Impact Factor 55.254

72) Virological profiles in hepatitis B virus/hepatitis C virus coinfecting patients under interferon plus ribavirin therapy.

Saitta C, Pontisso P, Brunetto MR, Fargion S, Gaeta GB, Niro GA, Picciotto A, Smedile A, **Squadrito G**, Raimondo G.

Antivir Ther. 2006;11 :931-4.

Impact Factor 2.146

73) Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.

Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D, Raimondo G.

Cancer. 2006; 15; 106: 1326-1330.

Impact Factor 6.537

74) Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds

Galeano M, Altavilla D, Bitto A, Minutoli L, Calò M, Lo Cascio P, Polito F, Giugliano G, **Squadrito G**, Mioni C, Giuliani D, Venuti FS, Squadrito F.

Cr Care Med 2006; 34-4; 1139-46

Impact Factor 6.63

75) Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients.

Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, **Squadrito G**, Tono N. Associazione Italiana Studio Fegato Cooperative Group.

Hepatology. 2006; 43: 100-107.

Impact Factor 14.079

76) Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones.

Pollicino T, Belloni L, Raffa G, Pediconi N, **Squadrito G**, Raimondo G, Levrero M.

Gastroenterology. 2006;130:823-37.

Impact Factor 20.773

77) Activation of the cholinergic anti-inflammatory pathway reduces NF-kappa B activation, blunts TNF-alpha production, and protects against splanchnic artery occlusion shock

Altavilla D, Guarini S, Bitto A, Mioni C, Giuliani D, Biagini A, **Squadrito G**, Minutoli L, Venuti FS, Messineo F, De Meo V, Bazzani C, Squadrito F.

Shock 2006; 25; 500-06.

Impact Factor 3.005

78) Is there a downgrading in the alert about the hepatitis B virus infection in Italy?

Raimondo G, Isgrò G, Caccamo G, Pollicino T, **Squadrito G**. Calabrian HBV Study Group

Dig Liver Dis. 2007 Mar;39(3):257-61.

Impact Factor 3.287

79) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma.

Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, **Squadrito G**, Levrero M, Raimondo G,

Hepatology. 2007 Feb;45(2):277-85.

Impact Factor 14.079

80) Occult hepatitis B virus infection.

Raimondo G, Pollicino T, Cacciola I, **Squadrito G**.

J Hepatol 2007 Jan;46(1):160-70.

Impact Factor 15.04

81) Celiac Disease and Non-organ-specific Autoantibodies in Patients with Chronic Hepatitis C Virus Infection.

Ruggeri C, La Masa AT, Rudi S, **Squadrito G**, Di Pasquale G, Maimone S, Cacciamo G, Pellegrino S, Raimondo G, Magazzù G.

Dig Dis Sci. 2008 Jan 31;

Impact Factor 2.819

82) Occult hepatitis B virus in liver tissue of individuals without hepatic disease.

Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, **Squadrito G**, Pollicino T.

J Hepatol. 2008 Feb 13;

Impact Factor 15.04

83) Statements from the Taormina expert meeting on occult hepatitis B virus infection.

Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, MichalaK T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, **Squadrito G**, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F.

J Hepatol. 2008; 49: 652-657

Impact Factor 15.04

84) Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.

Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, **Squadrito G**, Di Marco V, Craxì A, Raimondo G.

Antiv Ther 2009; 14; 649-54.

Impact Factor 2.146

85) An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.

Maimone S, Calvaruso V, Pleguezuelo M, **Squadrito G**, Amaddeo G, Jacobs M, Khanna P, Raimondo G, Dusheiko G

J Viral Hepat. 2009 Nov;16(11):769-74.

Impact Factor 4.237

86) Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

Prati D, Gasbarrini A, Mazzotta F, Sagnelli E, Carosi G, Abrescia N, Alberti A, Ambu S, Andreone P, Andriulli A, Angelico M, Antonucci G, Ascione A, Belli LS, Bruno R, Bruno S, Burra P, Camma C, Caporaso N, Cariti G, Cillo U, Coppola N, Craxi A, ; De Luca A, De Martin E, Di Marco V, Fagiuoli S, Ferrari C, Gaeta GB, Galli M, Grieco A, Grossi P, Licata A, Maida I, Mangia A, Marino N, Maserati R, Missale G, Mondelli M, Nasta P, Niro G, Persico M, Petrelli E, Picciotto A, Piscaglia F, Pollicino T, Prati D, Puoti C, Puoti M, Raimondo G, Rumi MG, Sagnelli E, Santantonio T, Smedile A, **Squadrito G**, Baroni GS, Talian, G, Tavio M, Toti M, Bonino F, Brunetto MR, Cacopardo B, Caremani M, Cauda R, Colombo M, Di Perri G, Donato F, Farci P, Fattovich G, Filice G, Ghinelli F, Guadagnino V, Lazzarin A, Levrero M, Licata G, Orani A, Paffetti A, Pastore G, Piccinino F, Pizzigallo E, Pontisso P, Portelli V, Rizzetto M, Rossi A, Stroffolini T, Ubaldi E.

Dig Liver Dis. 2010 Feb;42(2):81-91.

Impact Factor 3.287

87) Assesment of liver stiffness in subjects affected by familial combined hyperlipidaemia with hepatic steatosis.

Riggio S, Mamone F, Mandraffino G, Maimone S, Alibrandi A, Manti L, Saitta C, Tripodi PF, Sardo MA, **Squadrito G**, Saitta A.

Eur J Clin Invest. 2010 Aug;40(8):722-8.

Impact Factor 3.086

88) Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B

Mangano C, **Squadrito G**, Cacciola I, Carpentieri M, Foti G, Raimondo G.

Ann Hepatol. 2011 Jan 3;10(1):84-7.

Impact Factor 1.576

89) Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy.

Cacciola I, Messineo F, Cacopardo B, Di Marco V, Galli C, **Squadrito G**, Musolino C, Saitta C, Pollicino T, Raimondo G.

Dig Liver Dis. 2011 Dec;43(12):996-1000.

Impact Factor 3.287

90) Fibroscan: a new noninvasive method for evaluation of liver dysfunction in Turner syndrome(1).

Messina MF, **Squadrito G**, Valenzise M, Maimone S, Iannelli S, Arrigo T, Cacciola I, Civa R, D'Agata V, Raimondo G, De Luca F.

Eur J Clin Invest. 2011; 41 (2): 183-8.

Impact Factor 3.086

91) Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis.

Di Marco V, Calvaruso V, Iacò A, Bronte F, Biasi L, Prestini K, Sacchi P, Amaddeo G, **Squadrito G**, Bruno R, Puoti M, Craxì A.

Gut 2011; 60(7); 1023

Impact Factor 17.016

92) Replicative and trascrptional activities of hepatitis B virus in patients coinfectd with hepatitis B and Delta Virus.

Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, **Squadrito G**, Cacciola I, Calvi C, Colucci G, Levrero M, Raimondo G.

Viol. 2011 Jan;85(1):432-9

Impact Factor 4.368

93) Impact of Hepatitis B virus (HBV) pre S/S genome variability on HBV surface antigen and HBV DNA serum levels.

Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, **Squadrito G**, Raimondo G.

Hepatology 2012, Jan 23. doi: 10.1002/hep.25592

Impact Factor 14.079

94) Fever and rhomboid target lesion in decompensated cirrhosis.

Cascio A, Stassi G, Cacciola I, Saitta C, **Squadrito G**.

95) NS3 genetic variability in hepatitis C virus genotype-1b isolates from liver specimens and blood samples of treatment naïve patients with chronic hepatitis C

Maimone S, Musolino C, **Squadrito G**, Raffa G, Pollicino T, Raimondo G.

Antiviral Therapy 2013, 18: 131-4.

Impact Factor 2.146

96) Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee, Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, **Squadrito G**, Toniutto P.

Dig Liver Dis. 2013 Sep;45(9):712-23.

Impact Factor 3.287

97) Randomised study comparing 48 and 96 weeks peginterferon α -2a therapy in genotype D HBeAg-negative chronic hepatitis B.

Lampertico P;Viganò M;Di Costanzo GG;Sagnelli E;Fasano M;Di Marco V;Boninsegna S;Farci P;Fargion S;Giuberti T;Iannacone C;Regep L;Massetto B;Facchetti F;Colombo M;Andreone P; Riili A; Scuteri A; Cursaro C; Andriulli A; Niro GA; Angarano G; Fasano M; Santantonio TA; Palattella MS; Brunetto M; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Sacco R; Bruno S; Bollani S; Chiesa A; Carosi G; Baiguera C; Rossi S; Zaltron S; Puoti M; Colombo M; Lampertico P; Viganò M; Cozzolongo R; Giannuzzi V; Craxì A; Di Marco V; Calvaruso V; Venezia G; Di Costanzo GG; Lanza AG; Di Perri G; Cariti G; Mollaretti O; De Blasi T; Kulmiye C; Rostagno R; Farci P; Lai ME; Serra G; Chessa L; Balestrieri C; Cauli C; Fargion SR; Bertelli C; Fatta E; Fattovich G; Pasino M; Zanni S; Olivari N; Zagni I; Ferrari C; Schivazappa S; Giuberti T; Laccabue D; Penna A; Gaeta G; Stanzone M; Stornaiuolo G; Martines D; Boninsegna S; Raimondo G; Caccamo G; **Squadrito G**; Isgrò G; Rizzetto M; Lagget M; Carezzi S; Ruggiero G; Marrone A; Sagnelli E; Messina V; Di Caprio DU; Selva V; Toniutto P.

Gut 2013; 62; 290-98.

Impact Factor 17.06

98) Impact of Occult Hepatitis B Virus Infection on the Outcome of Chronic Hepatitis C

Squadrito G, I Cacciola, Alibrandi A, Pollicino T, Raimondo G.

J Hepatol. 2013; 59; 696-70.

Impact Factor 15.04

99) Randomised study comparing 48 and 96 weeks of peginterferon alfa-2a therapy genotype D HBeAg negative chronic hepatitis B.

Lampertico P, Viganò M, Di Costanzo GG et al PegBeLiver Study Group (Andreone P Riili A, et al **Squadrito G**).

Gut 2013; 62; 290-8.

Impact Factor 17.06

100) Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.

Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C.

J Viral Hepat. 2013 Nov;20(11):790-800.

Impact Factor 4.122

101) Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group.

Hepatology 2014 Jun;59(6):2101-9

Impact Factor 14.079

102) The clinical significance of occult HBV infection.

Squadrito G, Spinella R, Raimondo.

Ann Gastroenterol 2014;27(1):15-19.

Impact Factor 1.25

103) An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, **Squadrito G**, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators.

Dig Liver Dis. 2014 Jun 20.

Impact Factor 3.287

104) Case report: atrial fibrillation after intravenous administration of iodinated contrast medium in a patient with hepatocellular carcinoma. Maimone S, Filomia R, Saitta A, Raimondo G, **Squadrito G**.

Medicine (Baltimore) 2015 Sep;94(35):e1406. doi: 10.1097/MD

Impact Factor 2.28

105) Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Moleti MC, Giuffrida G, Sturniolo G, **Squadrito G**, Campennì A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marinò F.

Endocrine 2016; doi: 10.1007/s12020-016-0928-3

Impact Factor 3.179

106) Use of a balanced dual cyclooxygenase-1/2 and 5-lipoxygenase inhibitor in experimental colitis

Pallio G, Bitto A, Pizzino G, Galfo F, Irrera N, Minutoli L, Arcoraci V, **Squadrito G**, Macrì A, Squadrito F, Altavilla D.

Eur J Pharmacol 2016; 789; 152-62.

Impact Factor 3.04

107) The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases

Cartabellotta, F.; Di Marco, V.; Craxì, A.; Almasio, P.; Cammà, C.; Calvaruso, V.; Petta, S.; Colletti, P.; Mazzola, G.; Montalto, G.; Licata, A.; Giannitrapani, L.; Prestileo, T.; Di Lorenzo, F.; Dalle Nogare, R.; Sanfilippo, A.; Ficalora, A.; Madonia, S.; Tinè, F.; Malizia, G.; Vassallo, R.; Volpes, R.; Cacciola, I.; Caccamo, G.; Maimone, S.; Saitta, C.; **Squadrito G.**; Raimondo, G.; Tripodi, N.; D'Andrea, S.; Bertino, G.; Ardiri, A. L.; Proiti, Ma; Frazzetto, E.; Rigano, G.; Montineri, A.; Larocca, L. N.; Iacobello, C.; Cacopardo, B.; Benanti, F.; Russello, M.; Benigno, R.; Mannino, G.; Davì,

A.; Di Rosolini, M. A.; Digiacomio, A.; Fuduli, G.; Scifo, G.; Di Stefano, M.; Portelli, V.; Savalli, F.; Geraci, C.; Scalici, I.; Gioia, G.; Magro, A.; Alaimo, G.; Salvo, A.; Averna, A.; Lomonaco, F.; Quattrocchi, U.; Guarneri, L.; Maffeo, F.; Falzone, E.; Pulvirenti, F.

Eur Rev Med Pharm Sci 2016; 20; 11-16

Impac factor 1.981

108) Adenosine Receptor Stimulation by Polydeoxyribonucleotide Improves Tissue Repair and Symptomology in Experimental colitis.

Pallio G, Bitto A, Pizzino G, Galfo F, Irrera N, Squadrito F, **Squadrito G**, Pallio S, Anastasi GP, Cutroneo G, Macrì A, Altavilla D.

Front Pharmacol 2016; 7; 273; 1-13

Impact factor 3.831

109) Atrial fibrillation in patients with cirrhosis.

Mwalitsa JP, Maimone S, Filomia R, Alibrandi A, Saitta A, Caccamo G, Cacciola I, Spinella R, Oliva G, Lembo T, Vadalà D, Gambino G, Raimondo G and **Squadrito G**.

Liver 2016; 36 395-400.

Impact Factor 4.5

110) Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography.

Filomia R, Maimone S, Caccamo G, Saitta C, Visconti L, Alibrandi A, Caloggero S, Bottari A, Franzè MS, Gambino CG, Lembo T, Oliva T, Cacciola I, Raimondo G, **Squadrito G**.

Medicine (Baltimore) 2016;95; 38; 1-5

Impact Factor 2.028

111) Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group: Borsellino Z, Cuccia L, Maggio A, Madonia S, Fiorenza F, Salvo A, Gerardi C, Caruso V, Russello M, Fidone C, Davì A, **Squadrito G**, Aulenti G, Filosa A, Cianciulli P, Eliana Lai M, Piga A

Dig Liver Dis. 2016 Feb 21.

Impact Factor 3.061

112) Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.

Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, **Squadrito G**, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV).

Aliment Pharmacol Ther 2017 Oct;46(7):688-695

Impact Factor 7.357

113) Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care.

Cacciola I, Scoglio R, Alibrandi A, **Squadrito G**, Raimondo G; SIMG-Messina Hypertransaminasemia Study Group.

114) A Combination of Different Diagnostic Tools Allows Identification of Inactive Hepatitis B Virus Carriers at a Single Time Point Evaluation.

Maimone S, Caccamo G, **Squadrito G**, Alibrandi A, Saffioti F, Spinella R, Raffa G, Pollicino T, Raimondo G.

Liver Int. 2017; 37 (3): 362-68.

Impact Factor 4.5

115) Mucocutaneous toxicity during simeprevir treatment for hepatitis C. A single institution, retrospective case series.

Borgia F, Cacciola I, Filomia R, Vaccaro M, **Squadrito G**, Cannavò SP.

Br J Clin Pharmacol. 2017 May;83(5):1152-1154. doi: 10.1111/bcp.13221 Impact Factor 3.830

116) Elective endoscopic variceal ligation is not a risk factor for bacterial infection in patients with liver cirrhosis.

Maimone S, Saffioti F, Filomia R, Caccamo G, Saitta C, Pallio S, Consolo P, Sabatini S, Sitajolo K, Franzè MS, Cacciola I, Raimondo G, **Squadrito G**.

Dig Liver Dis. 2018;50(4):366-369.

Impact Factor 3.061

117) Erectile dysfunction in compensated liver cirrhosis.

Maimone S, Saffioti F, Oliva G, Di Benedetto A, Alibrandi A, Filomia R, Caccamo G, Saitta C, Cacciola I, Pitrone C, **Squadrito G**, Raimondo G

Dig Liver Dis. 2018 Oct 29. 1-7

Impact Factor 3.287

118) Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents.

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacoimo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, **Squadrito G**, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV).

Gastroenterology. 2018;155-2; 411-21

Impact Factor 20.773

119) Flavocoxid exerts a potent antiviral effect against hepatitis B virus.

Pollicino T, Musolino C, Irrera N, Bitto A, Lombardo D, Timmoneri M, Minutoli L, Raimondo G, **Squadrito G**, Squadrito F, Altavilla D.

Inflamm Res. 2018 Jan;67(1):89-103.

Impact Factor 2.99

120) Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis.

Cacciola I, Filomia R, Alibrandi A, Franzè MS, Caccamo G, Maimone S, Saitta C, Saffioti F, **Squadrito G**, Raimondo G.

121) Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.

Lampertico P, Brunetto MR, Craxì A, Gaeta GB, Rizzetto M, Rozzi A, Colombo M; HERMES Study Group (Antonio D, Andreone P, Antonio D, Brancaccio G, Bronte F, Bruzzone L, Caccamo G, Caccianotti B, Calvaruso V, Chessa L, Ciarallo M, Coco B, Colombatto P, Cursaro C, D'Aluisio D, Demelia L, Di Marco V, Dissegna D, Invernizzi F, Lenisa I, Lembo T, Levrero M, Marchese V, Mangia G, Picciotto A, Pierconti S, Antonio D, Raimondo G, Rastelli C, Rizzo V, Santantonio T, Scuteri A, Sorbello O, **Squadrito G**, Subic M, Toniutto P, Vukotic R.)

J Viral Hepat. 2019; 26; 11825

Impact Factor 4.122

122) Behaviour of occult HBV infection in HCV-infected patients under treatment with direct-acting antivirals.

Musolico C, Cacciola I, Tripodi G, Lombardo D, Raffa G, Alibrandi A, **Squadrito G**, Raimondo G.

Antivir Ther. 2019; Jan 10.

Impact Factor 2.146

Elenco delle pubblicazioni più significative

- 1) Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin's lymphoma and without liver disease.
Musolino C, Campo S, Pollicino T, **Squadrito G**, Spatari G, Raimondo G.
Haematologica. 1996; 81(2): 162-4 Impact Factor 9.09

- 2) Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C.
Le Gun B, **Squadrito G**, Nalpas B, Berthelot P, Pol , Brechot C.
Hepatology. 1997; 25: 1250-4. Impact Factor 14.079

- 3) Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.
Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, Pol , Brechot C
Gastroenterology. 1997; 113: 567-72. Impact Factor 20.773

- 4) Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection.
Leone F, Zylberberg H, **Squadrito G**, Le Gun B, Berthelot P, Pol , Brechot C
J Hepatol. 1998; 29: 689-94. Impact Factor 15.04

- 5) Epidemiological and virological analysis of couples infected with hepatitis C virus.
Zylberberg H, Thiers V, Lagorce D, **Squadrito G**, Leone F, Berthelot P, Brechot C, Pol S.
Gut 1999; 45: 112-6. Impact Factor 17.016

- 6) Long term response to interferon alpha is unrelated with "interferon sensitivity determining region" variability in patients with chronic hepatitis c virus-1b infection.
Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, Lo Iacono O, Siciliano R, Levrero M, Raimondo G.
J Hepatol 1999; 30: 1023-7 Impact Factor 15.04

- 7) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I, Pollicino T, **Squadrito G**, Cerenza G, Orlando ME, Raimondo G
N Engl J Med 1999; 1; 341: 22-6 Impact Factor 79.258

8) Occult hepatitis B virus infection.

Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, Pollicino T, **Squadrito G**, Tiribelli C.
Dig Liver Dis. 2000;32:822-6. Impact Factor 3.287

9) Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.

Cacciola I, Pollicino T, **Squadrito G**, Cerenza G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G,
Raimondo G.

Hepatology. 2000; 31: 507-12. Impact Factor 14.079

10) Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women

Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, D'anna R, Lasco A, **Squadrito G**, Gaudio A,
Cancellieri F, Arcoraci V, Squadrito F.

Art Thromb Vascul Biol 2000; 21; 1512-19. Impact Factor 6.089

11) Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin

Campo S, Restuccia T, Villari D, Raffa G, Cucinotta D, **Squadrito G**, Pollicino T, Raimondo G.

Liver. 2001 ;21-4:233-6. Impact factor 4.5

12) Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection.

Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, Brancatelli S, Di Marco V, Picciotto A, Colucci
G, Craxì A, Raimondo G

Am J Gastroenterol 2002; 97 (6):1518-1523 Impact Factor 10.237

13) The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women

Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, Caputi AP,
Squadrito G.

Atherosclerosis 2002; 163/2; 339-47. Impact Factor 4.467

14) Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.

Cacciola I, Cerenza G, Pollicino T, **Squadrito G**, Castellaneta S, Zanetti AR, Mieli-Vergani G, Raimondo G.

J Hepatol 2002; 36(3):426-432 Impact Factor 15.04

15) Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study

Squadrito F; Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, D'anna R, Corrado F, Ruggeri P, Frisina N,
Squadrito G.

Am J Med 2003; 114; 470-76.

Impact Factor 5.561.

16) Clinical Virology of hepatitis B virus infection.

G.Raimondo, T. Pollicino, **G. Squadrito**

Journal of Hepatology, 2003, 39 Suppl 1:S26-30.

Impact Factor 15.04

17) Efferent vagal fibre stimulation blunts nuclear factor-kappa B activation and protects against hypovolemic hemorrhagic shock

Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H, **Squadrito G**, Minutoli L, Bertolini A, Marini R, Adamo EB, Venuti FS, Squadrito F.

Circulation 2003; 107-8; 1189-94.

Impact Factor 18.8

18) Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin system in early postmenopausal women

Crisafulli A, Altavilla D, **Squadrito G**, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'anna R, Corrado F, Bartolone S, Frisina N, Squadrito F.

J Clin Endoc 2004; 89-1; 188-92.

Impact Factor 5.789

19) Is investigation of hepatitis C virus (HCV)-NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?

Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G.

J Viral Hepatitis 2002; 5: 360-369.

Impact Factor 4.237

20) Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases.

Raimondo G, Costantino L, Cacciamo G, Pollicino T, **Squadrito G**, Cacciola I, Brancatelli S.

J Hepatol. 2004; 40: 515-9

Impact Factor 15.04

21) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection

Pollicino T, **Squadrito G**, Cerenzia G, Cacciola I, Raffa G, Craxì A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G.

Gastroenterology. 2004;126:102-10.

Impact Factor 20.773

22) What is the clinical impact of occult hepatitis B virus infection?

Raimondo G, Pollicino T, **Squadrito G**.

23) Virological profiles in hepatitis B virus/hepatitis C virus coinfecting patients under interferon plus ribavirin therapy.
Saitta C, Pontisso P, Brunetto MR, Fargion S, Gaeta GB, Niro GA, Picciotto A, Smedile A, **Squadrito G**, Raimondo G.
Antivir Ther. 2006;11 :931-4. Impact Factor 2.146

24) Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D, Raimondo G.
Cancer. 2006; 15; 106: 1326-1330. Impact Factor 6.537

25) Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfecting patients.
Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, **Squadrito G**, Tono N. Associazione Italiana Studio Fegato Cooperative Group.
Hepatology. 2006; 43: 100-107. Impact Factor 14.079

26) Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones.
Pollicino T, Belloni L, Raffa G, Pediconi N, **Squadrito G**, Raimondo G, Levrero M.
Gastroenterology. 2006;130:823-37. Impact Factor 20.773

27) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma.
Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, **Squadrito G**, Levrero M, Raimondo G,
Hepatology. 2007 Feb;45(2):277-85. Impact Factor 14.079

28) Occult hepatitis B virus infection.
Raimondo G, Pollicino T, Cacciola I, **Squadrito G**.
J Hepatol 2007 Jan;46(1):160-70. Impact Factor 15.04

29) Occult hepatitis B virus in liver tissue of individuals without hepatic disease.
Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, **Squadrito G**, Pollicino T.
J Hepatol. 2008 Feb 13; Impact Factor 15.04

30) Statements from the Taormina expert meeting on occult hepatitis B virus infection.

Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, MichalaK T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, **Squadrito G**, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F.
J Hepatol. 2008; 49: 652-657 Impact Factor 15.04

31) Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, **Squadrito G**, Di Marco V, Craxì A, Raimondo G.
Antiv Ther 2009; 14; 649-54. Impact Factor 2.146

32) An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.
Maimone S, Calvaruso V, Pleguezuelo M, **Squadrito G**, Amaddeo G, Jacobs M, Khanna P, Raimondo G, Dusheiko G
J Viral Hepat. 2009 Nov;16(11):769-74. Epub 2009 Aug 26. Impact Factor 4.237

33) Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting
Prati D, Gasbarrini A, Mazzotta F, Sagnelli E, Carosi G, Abrescia N, Alberti A, Ambu S, Andreone P, Andriulli A, Angelico M, Antonucci G, Ascione A, Belli LS, Bruno R, Bruno S, Burra P, Camma C, Caporaso N, Cariti G, Cillo U, Coppola N, Craxi A, ; De Luca A, De Martin E, Di Marco V, Faggiuoli S, Ferrari C, Gaeta GB, Galli M, Grieco A, Grossi P, Licata A, Maida I, Mangia A, Marino N, Maserati R, Missale G, Mondelli M, Nasta P, Niro G, Persico M, Petrelli E, Picciotto A, Piscaglia F, Pollicino T, Prati D, Puoti C, Puoti M, Raimondo G, Rumi MG, Sagnelli E, Santantonio T, Smedile A, **Squadrito G**, Baroni GS, Talian, G, Tavio M, Toti M, Bonino F, Brunetto MR, Cacopardo B, Caremani M, Cauda R, Colombo M, Di Perri G, Donato F, Farci P, Fattovich G, Filice G, Ghinelli F, Guadagnino V, Lazzarin A, Levrero M, Licata G, Orani A, Paffetti A, Pastore G, Piccinino F, Pizzigallo E, Pontisso P, Portelli V, Rizzetto M, Rossi A, Stroffolini T, Ubaldi E.
Dig Liver Dis. 2010 Feb;42(2):81-91. Impact Factor 3.287

34) Replicative and trascrptional activities of hepatitis B virus in patients coinfectd with hepatitis B and Delta Virus.
Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, **Squadrito G**, Cacciola I, Calvi C, Colucci G, Levrero M, Raimondo G.
Virol. 2011 Jan;85(1):432-9 Impact Factor 4.368

35) Impact of Hepatitis B virus (HBV) pre S/S genome variability on HBV surface antigen and HBV DNA serum levels.
Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, **Squadrito G**, Raimondo G.
Hepatology 2012, Jan 23. doi: 10.1002/hep.25592 Impact Factor 14.079

36) Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee, Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, **Squadrito G**, Toniutto P.

Dig Liver Dis. 2013 Sep;45(9):712-23.

Impact Factor 3.287

37) Impact of Occult Hepatitis B Virus Infection on the Outcome of Chronic Hepatitis C

Squadrito G, I Cacciola, Alibrandi A, Pollicino T, Raimondo G.

J Hepatol. 2013; 59; 696-70.

Impact Factor 15.04

38) Randomised study comparing 48 and 96 weeks peginterferon α -2a therapy in genotype D HBeAg-negative chronic hepatitis B.

Lampertico P;Viganò M;Di Costanzo GG;Sagnelli E;Fasano M;Di Marco V;Boninsegna S;Farci P;Fargion S;Giuberti T;Iannacone C;Regep L;Massetto B;Facchetti F;Colombo M;Andreone P; Riili A; Scuteri A; Cursaro C; Andriulli A; Niro GA; Angarano G; Fasano M; Santantonio TA; Palattella MS; Brunetto M; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Sacco R; Bruno S; Bollani S; Chiesa A; Carosi G; Baiguera C; Rossi S; Zaltron S; Puoti M; Colombo M; Lampertico P; Viganò M; Cozzolongo R; Giannuzzi V; Craxì A; Di Marco V; Calvaruso V; Venezia G; Di Costanzo GG; Lanza AG; Di Perri G; Cariti G; Mollaretti O; De Blasi T; Kulmiye C; Rostagno R; Farci P; Lai ME; Serra G; Chessa L; Balestrieri C; Cauli C; Fargion SR; Bertelli C; Fatta E; Fattovich G; Pasino M; Zanni S; Olivari N; Zagni I; Ferrari C; Schivazappa S; Giuberti T; Laccabue D; Penna A; Gaeta G; Stanzione M; Stornaiuolo G; Martines D; Boninsegna S; Raimondo G; Caccamo G; **Squadrito G**; Isgrò G; Rizzetto M; Lagget M; Carezzi S; Ruggiero G; Marrone A; Sagnelli E; Messina V; Di Caprio DU; Selva V; Toniutto P.

Gut 2013; 62; 290-98.

Impact Factor 17.06

39) The clinical significance of occult HBV infection.

Squadrito G, Spinella R, Raimondo.

Ann Gastroenterol 2014;27(1):15-19.

Impact Factor 1.25

40) Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.

Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonna S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, **Squadrito G**, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV).

Aliment Pharmacol Ther 2017 Oct;46(7):688-695

Impact Factor 7.357

41) Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents.

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, **Squadrito G**, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV).

Gastroenterology. 2018;155-2; 411-21

Impact Factor 20.773